Insulin‐like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease

2021 ◽  
Author(s):  
Jiaqi Pan ◽  
Li Cen ◽  
Tianyu Zhou ◽  
Mengli Yu ◽  
Xueyang Chen ◽  
...  
Keyword(s):  
Liver Disease ◽  
Growth Factor ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Lipid Accumulation ◽  
Fatty Liver Disease ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Nonalcoholic Fatty Liver ◽  
Factor Binding

scholarly journals Nonalcoholic Fatty Liver Disease Is Associated with Low Circulating Levels of Insulin-Like Growth Factor-I

2011 ◽  
Vol 96 (10) ◽  
pp. E1640-E1644 ◽  
Author(s):  
Franco Arturi ◽  
Elena Succurro ◽  
Cristina Procopio ◽  
Elisabetta Pedace ◽  
Gaia Chiara Mannino ◽  
...  
Keyword(s):  
Liver Disease ◽  
Growth Factor ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Insulin Like Growth Factor ◽  
Nonalcoholic Fatty Liver ◽  
Factor I ◽  
Growth Factor I ◽  
Circulating Levels

Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1

2016 ◽  
Vol 61 (11) ◽  
pp. 3190-3198 ◽  
Author(s):  
Daniel Cabrera ◽  
Alex Ruiz ◽  
Claudio Cabello-Verrugio ◽  
Enrique Brandan ◽  
Lisbell Estrada ◽  
...  
Keyword(s):  
Liver Disease ◽  
Growth Factor ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Serum Insulin ◽  
Insulin Like Growth Factor ◽  
Nonalcoholic Fatty Liver

scholarly journals Circulating IGFBP-2 levels are inversely associated with the incidence of nonalcoholic fatty liver disease: A cohort study

2020 ◽  
Vol 48 (8) ◽  
pp. 030006052093521
Author(s):  
Ji Yang ◽  
Wenjing Zhou ◽  
Yue Wu ◽  
Liqian Xu ◽  
Yuming Wang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Liver Disease ◽  
Growth Factor ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Insulin Like Growth Factor ◽  
Nonalcoholic Fatty Liver

Objective The insulin-like growth factor (IGF) axis is essential for the body’s metabolism. The hepatokine, insulin-like growth factor-binding protein 2 (IGFBP-2), acts as a major regulator of this metabolism. We aimed to evaluate the role of serum IGFBP-2 in the incidence of nonalcoholic fatty liver disease (NAFLD). Methods This hospital-based prospective cohort study recruited residents from a health program from January to November 2013, and re-invited them for follow-up in 2016. The occurrence of NAFLD was noted and IGFBP-2 levels were evaluated by enzyme-linked immunosorbent assay at both visits. Results Of 763 participants at baseline, 296 completed the re-evaluation. Baseline serum IGFBP-2 levels were significantly lower in subjects with NAFLD compared with those without NAFLD. Circulating IGFBP-2 levels were negatively correlated with body mass index, waist-to-hip ratio, alanine transaminase, triglycerides, fasting glucose, and insulin. IGFBP-2 levels at follow-up decreased in subjects who developed NAFLD compared with those who did not. Higher circulating levels of IGFBP-2 at baseline were negatively associated with the incidence of NAFLD. Conclusion These results indicate that IGFBP-2 levels are inversely associated with the risk of NAFLD. This offers new insights into the role of circulating IGFBP-2, as an IGF-axis hepatokine, in the pathogenesis of hepatic steatosis.

scholarly journals Insulin-Like growth factor binding Protein-1, non-alcoholic fatty liver disease, and its relationship with fructose consumption in children with obesity

2019 ◽  
Vol 71 (5) ◽  
Author(s):  
Anaisa G. Flores-Ramírez ◽  
Lorena del R. Ibarra-Reynoso ◽  
Hilda Lissete López-Lemus ◽  
Montserrat Olvera-Juárez ◽  
Claudia Luevano-Contreras ◽  
...  
Keyword(s):  
Liver Disease ◽  
Growth Factor ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Alcoholic Fatty Liver ◽  
Factor Binding ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document